News

May 3, 2017: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.

August 17, 2016: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.

August 11, 2016: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company’s Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer.

May 15, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2015 prepared in accordance with International Financial Reporting Standards.

April 1, 2015: Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company is undertaking further analyses of its pivotal U.S. Phase 3 studies of NX-1207 for prostate enlargement (BPH).